FDA Breakthrough Therapy for Enpatoran

The US United States — Food and Drug Administration (FDA) granted Breakthrough Therapy designation to enpatoran, an investigational oral TLR7/8 inhibitor developed by Merck Group (through its healthcare business Merck KGaA — Merck Serono in the US and Canada), for the treatment of lupus with active cutaneous manifestations. The designation is supported by positive Phase 2 WILLOW study results showing clinically meaningful improvements in lupus symptoms, particularly skin manifestations. Merck has also initiated the global Phase 3 ELOWEN program to further evaluate enpatoran's efficacy and safety. This designation aims to expedite the development and review of enpatoran, which could become the first targeted therapy for lupus patients with active skin involvement, addressing a significant unmet medical need.